

allowable. Claim 1 has been identified as generic by the Examiner. The Examiner also requires that a listing of all claims readable upon this election of species be identified by the Applicants.

The Applicants herein elect group I above (claims 1 -11 drawn to a product, classified in class 435, subclass various) for prosecution in the current examination. Applicants also wish to elect new independent claim 15 for prosecution as a single disclosed species required by the Examiner for restriction. The subject matter of claim 15 encompasses the single disclosed species represented by pending claims 4, 5, 6, 8, 9, 10, and 11 and which pending claims are dependent upon claim 1.

IN THE CLAIMS:

Please add the following claim:

15 (New). A solid pharmaceutical composition suitable for the oral delivery of a pharmacologically active agent comprising:

31

- a. salmon calcitonin
- b. crospovidone
- c. 5 CNAC
- d. optionally, microcrystalline cellulose, and
- e. optionally, magnesium stearate.

REMARKS

Applicants have elected group I above and have added new claim 15, which is drawn to the disclosed species of the solid pharmaceutical composition encompassed by pending claims 4, 5, 6, 8, 9, 10, and 11, which pending claims are ultimately dependent upon claim 1, for current prosecution in the case.

Claim 1 claims a solid pharmaceutical composition suitable for the oral delivery of a pharmacologically active agent comprising

- a. therapeutically-effective amount of a pharmacologically active agent;
- b. a crospovidone or povidone; and
- c. a delivery agent for said pharmacologically active agent.

Claim 4 claims a composition according to claim 1 wherein the active agent is salmon calcitonin.

Claim 5 claims a composition according to claim 1 comprising crospovidone.

Claim 6 claims a composition according to claim 1 wherein the delivery agent is 5CNAC.